TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE)
$17.66 0.22 (1.2615%)
Analysed TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE) News Sources
Moderna, Takeda and Capricor on the verge of notching big drug approvals
13-07-2026
pharmavoice.com
Takeda and Indonesia partner on plasma-derived therapies
13-07-2026
pharmaceutical-technology.com
Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
15-07-2026
yahoo.com
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
16-07-2026
yahoo.com
Change in Siegfried's Management Team
16-07-2026
yahoo.com
Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading
24-07-2026
yahoo.com
Takeda (TSE:4502) Expands In Indonesia As Psoriasis Drug Delivers Phase 3 Data
26-07-2026
yahoo.com
Takeda Pharmaceutical (TSE:4502) Reports New Phase 3 Psoriasis Data, Is The 10% Discount Enough?
26-07-2026
yahoo.com
Takeda (TSE:4502) Stock Looks Below Fair Value While Broader Checks Stay Mixed
26-07-2026
yahoo.com
How New Phase 3 Psoriasis Data For Zasocitinib At Takeda Pharmaceutical (TSE:4502) Has Changed Its Investment Story
27-07-2026
yahoo.com
What is the current price of TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE)?
The current price of TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE) is $17.66.
TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE) absolute price change since previous trading day?
The absolute price change of TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE) since the previous trading day is $0.22.
TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE) percentage price change since previous trading day?
The percentage price change of TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE) since the previous trading day is 1.2615%.
What is the most recent average sentiment score for TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE)?
The most recent average sentiment score for TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE) is 58 out of 100.
What is the most recent average sentiment for TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE)?
The most recent sentiment for TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE) is .
SEC-8K** Filing Available For TAKEDA PHARMACEUTIC-SP ADR (TAK:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.